National Pension Service Raises Stock Holdings in Zoetis Inc. $ZTS

by · The Markets Daily

National Pension Service lifted its stake in Zoetis Inc. (NYSE:ZTS – Free Report) by 9.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 839,875 shares of the company’s stock after buying an additional 73,785 shares during the quarter. National Pension Service owned approximately 0.20% of Zoetis worth $60,353,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in ZTS. Louisiana State Employees Retirement System purchased a new stake in Zoetis in the 1st quarter worth about $2,542,000. Wealthfront Advisers LLC lifted its stake in shares of Zoetis by 80.2% during the 2nd quarter. Wealthfront Advisers LLC now owns 76,113 shares of the company’s stock worth $5,469,000 after acquiring an additional 33,873 shares during the last quarter. Deutsche Bank AG grew its position in Zoetis by 19.1% in the 4th quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock valued at $699,331,000 after acquiring an additional 891,921 shares during the last quarter. Pincus Capital Management LP bought a new stake in shares of Zoetis during the fourth quarter worth $2,109,000. Finally, Diamond Hill Capital Management LLC Investment Advisor boosted its stake in shares of Zoetis by 21.5% during the second quarter. Diamond Hill Capital Management LLC Investment Advisor now owns 3,557,436 shares of the company’s stock valued at $255,637,000 after purchasing an additional 629,974 shares during the period. 92.80% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have issued reports on ZTS. Zacks Research cut shares of Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. HSBC dropped their price objective on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. JPMorgan Chase & Co. cut their price target on Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Zoetis in a research note on Wednesday. Finally, UBS Group reduced their price target on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $101.08.

Check Out Our Latest Research Report on Zoetis

Zoetis Price Performance

Shares of NYSE:ZTS opened at $73.05 on Friday. Zoetis Inc. has a twelve month low of $71.00 and a twelve month high of $150.05. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The company has a market cap of $30.19 billion, a PE ratio of 12.03, a price-to-earnings-growth ratio of 1.70 and a beta of 0.73. The company’s 50 day moving average is $75.56 and its 200 day moving average is $91.97.

Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business’s revenue for the quarter was down .2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 6.2 EPS for the current year.

About Zoetis

(Free Report)

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company’s product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.

Read More

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).